DEBRISOQUINE OXIDATION PHENOTYPE AND SUSCEPTIBILITY TO LUNG-CANCER

被引：59

作者：

SPEIRS, CJ ^{[1
]}

MURRAY, S ^{[1
]}

DAVIES, DS ^{[1
]}

MABADEJE, AFB ^{[1
]}

BOOBIS, AR ^{[1
]}

机构：

[1] ROYAL POSTGRAD MED SCH, DEPT CLIN PHARMACOL, DU CANE RD, LONDON W12 0NN, ENGLAND

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1990年 / 29卷 / 01期

基金：

英国惠康基金;

关键词：

D O I：

10.1111/j.1365-2125.1990.tb03608.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

1. It has been suggested that poor metabolisers of debrisoquine are at reduced risk of developing lung cancer from smoking cigarettes. This has been investigated in 82 patients with established cancer of the lung. 2. The frequency of poor metaboliser subjects was not different from that in the normal population. 3. There was no tendency for subjects with lung cancer to metabolise debrisoquine more rapidly than non‐cancer subjects. 4. It is concluded that debrisoquine metabolic phenotype is not a good predictor of risk of developing lung cancer in the population at large. 1990 The British Pharmacological Society

引用

页码：101 / 109

页数：9

共 50 条

[1] DEBRISOQUINE OXIDATION PHENOTYPE AND SUSCEPTIBILITY TO LUNG-CANCER
BOOBIS, AR
DAVIES, DS
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (04) : 653 - 656
[2] IS THERE A LINK BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND LUNG-CANCER SUSCEPTIBILITY
HORSMANS, Y
DESAGER, JP
HARVENGT, C
[J]. BIOMEDICINE & PHARMACOTHERAPY, 1991, 45 (08) : 359 - 362
[3] Relationship between debrisoquine oxidation phenotype and susceptibility to lung cancer
Sardas, S
Cok, I
[J]. TOXICOLOGY, 2001, 164 (1-3) : 153 - 153
[4] LUNG-CANCER AND THE DEBRISOQUINE METABOLIC PHENOTYPE
CAPORASO, NE
TUCKER, MA
HOOVER, RN
HAYES, RB
PICKLE, LW
ISSAQ, HJ
MUSCHIK, GM
GREENGALLO, L
BUIVYS, D
AISNER, S
RESAU, JH
TRUMP, BF
TOLLERUD, D
WESTON, A
HARRIS, CC
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (15) : 1264 - 1272
[5] POLYMORPHIC OXIDATION OF DEBRISOQUINE IN LUNG-CANCER PATIENTS
BENITEZ, J
LADERO, JM
JARA, C
CARRILLO, JA
COBALEDA, J
LLERENA, A
VARGAS, E
MUNOZ, JJ
[J]. EUROPEAN JOURNAL OF CANCER, 1991, 27 (02) : 158 - 161
[6] LUNG-CANCER RISK, OCCUPATIONAL EXPOSURE, AND THE DEBRISOQUINE METABOLIC PHENOTYPE
CAPORASO, N
HAYES, RB
DOSEMECI, M
HOOVER, R
AYESH, R
HETZEL, M
IDLE, J
[J]. CANCER RESEARCH, 1989, 49 (13) : 3675 - 3679
[7] LACK OF A RELATIONSHIP BETWEEN THE POLYMORPHISM OF DEBRISOQUINE OXIDATION AND LUNG-CANCER
DUCHE, JC
JOANNE, C
BARRE, J
DECREMOUX, H
DALPHIN, JC
DEPIERRE, A
BROCHARD, P
TILLEMENT, JP
BECHTEL, P
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (05) : 533 - 536
[8] THE DEBRISOQUINE METABOLIC PHENOTYPE AND DNA-BASED ASSAYS - IMPLICATIONS OF MISCLASSIFICATION FOR THE ASSOCIATION OF LUNG-CANCER AND THE DEBRISOQUINE METABOLIC PHENOTYPE
CAPORASO, NE
SHIELDS, PG
LANDI, MT
SHAW, GL
TUCKER, MA
HOOVER, R
SUGIMURA, H
WESTON, A
HARRIS, CC
[J]. ENVIRONMENTAL HEALTH PERSPECTIVES, 1992, 98 : 101 - 105
[9] DEBRISOQUINE METABOLISM AND LUNG-CANCER RISK
SHAW, GL
FALK, RT
DESLAURIERS, J
FRAME, JN
NESBITT, JC
PASS, HI
ISSAQ, HJ
HOOVER, RN
TUCKER, MA
[J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1995, 4 (01) : 41 - 48
[10] DEBRISOQUIN OXIDATION GENOTYPE AND SUSCEPTIBILITY TO LUNG-CANCER
AGUNDEZ, JAG
MARTINEZ, C
LADERO, JM
LEDESMA, MC
RAMOS, JM
MARTIN, R
RODRIGUEZ, A
JARA, C
BENITEZ, J
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (01) : 10 - 14

← 1 2 3 4 5 →